JP7358367B2 - 抗グリコｍｕｃ１抗体およびその使用 - Google Patents

抗グリコｍｕｃ１抗体およびその使用 Download PDF

Info

Publication number
JP7358367B2
JP7358367B2 JP2020543460A JP2020543460A JP7358367B2 JP 7358367 B2 JP7358367 B2 JP 7358367B2 JP 2020543460 A JP2020543460 A JP 2020543460A JP 2020543460 A JP2020543460 A JP 2020543460A JP 7358367 B2 JP7358367 B2 JP 7358367B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510307A (ja
Inventor
ホワイト，セイヤー
Original Assignee
ジーオー セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーオー セラピューティクス，インコーポレイテッド filed Critical ジーオー セラピューティクス，インコーポレイテッド
Publication of JP2021510307A publication Critical patent/JP2021510307A/ja
Priority to JP2023165289A priority Critical patent/JP2024001073A/ja
Application granted granted Critical
Publication of JP7358367B2 publication Critical patent/JP7358367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020543460A 2017-10-24 2017-10-24 抗グリコｍｕｃ１抗体およびその使用 Active JP7358367B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023165289A JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023165289A Division JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2021510307A JP2021510307A (ja) 2021-04-22
JP7358367B2 true JP7358367B2 (ja) 2023-10-10

Family

ID=66247577

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543460A Active JP7358367B2 (ja) 2017-10-24 2017-10-24 抗グリコｍｕｃ１抗体およびその使用
JP2023165289A Pending JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023165289A Pending JP2024001073A (ja) 2017-10-24 2023-09-27 抗グリコｍｕｃ１抗体およびその使用

Country Status (10)

Country Link
EP (1) EP3700936A4 (enExample)
JP (2) JP7358367B2 (enExample)
KR (2) KR102832078B1 (enExample)
CN (1) CN111479828B (enExample)
AU (1) AU2017436815B2 (enExample)
BR (1) BR112020008001A2 (enExample)
CA (1) CA3078812A1 (enExample)
IL (1) IL274202A (enExample)
MX (1) MX2020004220A (enExample)
WO (1) WO2019083506A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024001073A (ja) * 2017-10-24 2024-01-09 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11970546B2 (en) * 2020-07-31 2024-04-30 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof
AU2022333837A1 (en) * 2021-08-27 2024-03-14 Peptron, Inc. Novel anti-muc1 antibody and use thereof
US20230250190A1 (en) * 2021-12-21 2023-08-10 Merus N.V. Binding domains against cancer-associated muc1
CN114796498A (zh) * 2022-01-27 2022-07-29 中国农业大学 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用
WO2024213106A1 (zh) * 2023-04-13 2024-10-17 江苏恒瑞医药股份有限公司 特异性结合egfr和muc1的抗原结合分子、其药物偶联物及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors
US20160145343A1 (en) 2013-07-15 2016-05-26 Cell Signaling Technology, Inc, Anti-mucin 1 binding agents and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4976001A (en) * 2000-03-30 2001-10-15 Dyax Corp Mucin-1 specific binding members and methods of use thereof
JP2010505775A (ja) * 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CA2707689A1 (en) * 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US20170145108A1 (en) * 2014-02-05 2017-05-25 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
AU2017436815B2 (en) * 2017-10-24 2025-05-29 Go Therapeutics, Inc. Anti-glyco-muc1 antibodies and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors
US20160145343A1 (en) 2013-07-15 2016-05-26 Cell Signaling Technology, Inc, Anti-mucin 1 binding agents and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024001073A (ja) * 2017-10-24 2024-01-09 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用

Also Published As

Publication number Publication date
AU2017436815B2 (en) 2025-05-29
JP2021510307A (ja) 2021-04-22
KR102832078B1 (ko) 2025-07-08
JP2024001073A (ja) 2024-01-09
AU2017436815A1 (en) 2020-04-23
CN111479828A (zh) 2020-07-31
CA3078812A1 (en) 2019-05-02
CN111479828B (zh) 2024-07-05
MX2020004220A (es) 2020-10-05
KR20200067885A (ko) 2020-06-12
EP3700936A1 (en) 2020-09-02
WO2019083506A1 (en) 2019-05-02
IL274202A (en) 2020-06-30
BR112020008001A2 (pt) 2020-10-20
KR102608763B1 (ko) 2023-11-30
EP3700936A4 (en) 2021-05-26
KR20230165874A (ko) 2023-12-05

Similar Documents

Publication Publication Date Title
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
JP7358367B2 (ja) 抗グリコｍｕｃ１抗体およびその使用
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
JP2024536722A (ja) 抗グリコｃｍｅｔ抗体およびその使用
JP2024534910A (ja) 抗グリコｌａｍｐ１抗体およびその使用
JP2024531915A (ja) 抗グリコｍｕｃ抗体およびその使用
JP2024512324A (ja) 抗グリコｃｄ４４抗体およびその使用
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230927

R150 Certificate of patent or registration of utility model

Ref document number: 7358367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150